The Column Group operates as a venture ecosystem rather than a traditional VC fund, systematically creating single-drug biotech companies through its affiliated TCG Labs-Soleil engine instead of primarily backing existing startups. The fund has achieved documented outlier performance with a ~397% IRR on certain early-stage drug-discovery investments, distinguishing itself through deep scientific platform bets led by research-heavy leadership from the translational science community.